ReviewOncology letters2025

EGFR mutations in non-small cell lung cancer: Classification, characteristics and resistance to third-generation EGFR-tyrosine kinase inhibitors (Review).

Zhe Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.